Sol-Gel Technologies EBIT 2016-2024 | SLGL
Sol-Gel Technologies ebit from 2016 to 2024. Ebit can be defined as earnings before interest and taxes.
Sol-Gel Technologies Annual EBIT
(Millions of US $) |
| 2023 |
$-29 |
| 2022 |
$-16 |
| 2021 |
$3 |
| 2020 |
$-30 |
| 2019 |
$-26 |
| 2018 |
$-34 |
| 2017 |
$-32 |
| 2016 |
$-21 |
| 2015 |
$-10 |
Sol-Gel Technologies Quarterly EBIT
(Millions of US $) |
| 2024-06-30 |
$2 |
| 2024-03-31 |
$-7 |
| 2023-12-31 |
$-5 |
| 2023-09-30 |
$-6 |
| 2023-06-30 |
$-7 |
| 2023-03-31 |
$-11 |
| 2022-12-31 |
$-6 |
| 2022-09-30 |
$-4 |
| 2022-06-30 |
$-0 |
| 2022-03-31 |
$-6 |
| 2021-12-31 |
$14 |
| 2021-09-30 |
$1 |
| 2021-06-30 |
$-8 |
| 2021-03-31 |
$-4 |
| 2020-12-31 |
$-7 |
| 2020-09-30 |
$-9 |
| 2020-06-30 |
$-8 |
| 2020-03-31 |
$-7 |
| 2019-12-31 |
$-7 |
| 2019-09-30 |
$-8 |
| 2019-06-30 |
$-5 |
| 2019-03-31 |
$-6 |
| 2018-12-31 |
$-12 |
| 2018-09-30 |
$-8 |
| 2018-06-30 |
$-7 |
| 2018-03-31 |
$-6 |
| 2017-12-31 |
|
| 2017-09-30 |
|
| 2017-06-30 |
$-6 |
| 2016-12-31 |
|
| 2015-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.012B |
$0.002B |
|
Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies Ltd.is based in Israel.
|
